By Dr. Daniel Jinhag Baik, MD — Ophthalmologist and Head Director, nuneHIM Eye Center (Guro-gu, Seoul)
Quick answer: Yes — an oral medicine called pilocarpine can stimulate tear and saliva glands. Evidence is strongest for dryness linked to Sjögren’s syndrome. In everyday dry eye without Sjögren’s, a 2026 randomized trial did not find it superior to artificial tears, and systemic side effects (especially sweating) are common. It is a selective option after examination, not a first-line substitute for drops.
Key takeaways
- For Sjögren’s-related dry eye and dry mouth, oral pilocarpine has relatively clear symptom-improvement evidence from randomized trials.
- For general dry eye, a 2026 randomized controlled trial did not show oral pilocarpine superior to artificial tears.
- The most common side effect is increased sweating; asthma, acute iritis, and narrow- or closed-angle glaucoma are among the contraindications.
Patients who already use artificial tears several times a day often ask whether a dry eye pill exists. Oral pilocarpine has been available in Korea since 1998, and a new oral product was also approved in May 2026. Approvals and trial evidence mainly cover Sjögren’s dryness and radiation-related dry mouth — not every form of dry eye.
What is oral pilocarpine?
Artificial tears add moisture from the outside. Pilocarpine is a cholinergic agonist that stimulates muscarinic receptors — especially M3 receptors — on tear and salivary glands, signaling them to secrete more.
Two limits matter. First, the glands need remaining function; if autoimmune damage has largely destroyed gland tissue, the boost may be limited. Second, the drug is not eye-selective: sweat glands, the gut, cardiovascular pathways, and the airways can also respond, which explains systemic side effects.
In Korea, oral pilocarpine hydrochloride 5 mg is approved for dry eye or dry mouth in Sjögren’s syndrome, and for dry mouth after head-and-neck radiation that impairs salivary glands. It is a prescription medicine, not a blanket treatment for all dry eye.
Does it really increase tears?
Symptom relief and measured tear volume are not the same. Patients can feel less grit or burning even when Schirmer numbers do not clearly rise, if tear-film stability or the ocular surface improves.
Vivino et al., 1999 (Sjögren’s, n = 373)
A 12-week randomized, double-blind, placebo-controlled trial. Pilocarpine 5 mg four times daily improved dry eye and dry mouth symptoms versus placebo.
| Group | Global dry-eye symptom improvement |
|---|---|
| Pilocarpine | 42% |
| Placebo | 26% |
What 42% does not mean: It is not a cure rate, and not a 42% rise in tear volume — it is the share who reported overall dry-eye symptom improvement. Sweating occurred in 43.3% on 5 mg four times daily versus 7.2% on placebo.
Tsifetaki et al., 2003 (Sjögren’s, n = 85)
Three arms over 12 weeks: oral pilocarpine plus artificial tears; artificial tears alone; punctal occlusion plus artificial tears. The pilocarpine group improved more on subjective symptoms and rose-bengal staining. Schirmer testing did not show a statistically significant difference between groups.
Aragona et al., 2006 (n = 15)
After two months in Sjögren’s patients: less burning and foreign-body sensation, better symptoms, improved tear break-up time (BUT), and more conjunctival goblet cells (linked to mucin and tear-film stability). Small study — not generalizable to all dry eye.
2026 trial: oral pilocarpine vs artificial tears
Saad and colleagues (Medical Hypothesis, Discovery & Innovation in Ophthalmology, 2026) ran a randomized trial in general dry eye (not Sjögren’s-only): 120 people for eight weeks — oral pilocarpine versus 0.2% sodium hyaluronate drops.
| Outcome (after treatment) | Pilocarpine | Artificial tears |
|---|---|---|
| Dry Eye Quality of Life Score (DEQS) | 21.9 | 12.1 |
| Tear break-up time (TBUT) | 9.8 s | 11.8 s |
| Schirmer test | Improved | Improved |
Lower DEQS means less dry-eye burden (post-treatment means). Schirmer improved in both groups without a significant between-group difference. Both groups improved versus baseline, but tear-film stability and quality of life favored artificial tears.
In the pilocarpine arm (n = 60): sweating 63%, brow pain 28%, nausea 25% — none of these reported with artificial tears.
A pill is therefore not automatically stronger than drops. For typical dry eye, evidence does not support oral pilocarpine as a routine first-line replacement for topical care. This was one 8-week study of 120 people. Overall, the clearest support remains Sjögren’s-related dryness; in general dry eye it is a selective option.
After cataract or laser vision correction
Postoperative dry eye is common and can affect how clear vision feels even when the chart looks good.
Miura et al. (2022) reviewed 36 studies and, for new dry eye after surgery, pooled 9 studies (775 patients): random-effects estimate 37.4% (95% CI 22.6–52.3%); simple sum 206/775 (~26.6%). That pooled figure is not one clinic’s rate — it shows postoperative dry eye is not rare.
Ta et al. (2025) reported dry-eye–related changes after cataract surgery can persist through about three months. That does not mean everyone recovers at three months.
Common postoperative dryness does not prove oral pilocarpine works after cataract, LASIK, or LASEK. Direct evidence in those groups is limited. Care usually starts by assessing tear deficiency, tear-film instability, meibomian gland dysfunction (MGD), and inflammation, with topical treatment first.
Who might benefit — and who might not
1. Aqueous-deficient dry eye — too little watery tear. Sjögren’s is a classic cause; eyes and mouth often dry together. Here, pilocarpine may be considered.
2. Evaporative dry eye — tears evaporate too fast, often from MGD. Stimulating watery secretion may not fix the oil layer; lid hygiene, warm compresses, and — when selected — IPL may fit better.
3. Mixed dry eye — both mechanisms together are common; combination care usually beats one drug alone.
Severe symptoms alone do not automatically mean pilocarpine. Low tear production still needs Sjögren’s status and overall health reviewed first.
| Pros | Cons / limits |
|---|---|
| Stimulates gland secretion | Systemic side effects possible |
| Symptom evidence in Sjögren’s | Hard to apply to all dry eye |
| Possible help when dry mouth coexists | Sweating, urinary frequency, nausea |
| Mechanism different from drops | Multiple daily doses; variable response |
| Selective add-on option | Limited direct evidence after eye surgery |
Side effects and precautions
The most reported side effect is sweating (Vivino 1999: 43.3% vs 7.2% placebo; Saad 2026: 63% in the pilocarpine group). Different study designs — do not average those rates.
Also watch for: dehydration risk if sweating is heavy; nausea, abdominal discomfort, diarrhea; urinary frequency and flushing; blurred vision or reduced night vision (caution with night driving); heart-rate or blood-pressure changes and bronchoconstriction. Seek urgent care for breathing difficulty, fainting, severe dizziness, or strong palpitations.
Review carefully before use (contraindications or high caution): asthma; acute iritis; narrow- or closed-angle glaucoma; significant cardiovascular disease; COPD; gallstones/biliary disease; history of kidney stones; hepatic impairment; pregnancy or breastfeeding. Tell your clinician about beta-blockers, anticholinergics, and other heart-related medicines.
How it sits among other treatments
TFOS DEWS III (2025) stresses matching therapy to cause. Options are complementary, not interchangeable: preservative-free artificial tears (baseline lubrication); diquafosol drops (water/mucin support); cyclosporine drops (inflammation); warm compresses and lid hygiene (MGD); IPL in selected MGD cases; punctal plugs for selected aqueous deficiency; and oral pilocarpine mainly for Sjögren’s-related dryness.
Stimulating tears alone may not help severe MGD; lid care alone may not help major aqueous deficiency.
If drops are not enough — and desk-work tips
Useful tests may include tear break-up time (TBUT), Schirmer testing, corneal/conjunctival staining, meibomian assessment, symptom questionnaires (such as OSDI), and Sjögren’s-related evaluation when eyes and mouth are both dry or systemic clues appear.
Near Guro and Gasan Digital Complex, long screen hours cut blink rate; AC or heating plus low humidity often worsens symptoms. Try the 20-20-20 rule (every 20 minutes look about 6 m / 20 feet away for 20 seconds), place the monitor slightly below eye level, practice full blinks, and use warm compresses/lid hygiene when MGD is present. If frequent drops still fail, find which part of the tear film is failing rather than only increasing drop count. English consultations are available; bring medication lists and prior eye records.
FAQ
Is there really an oral medicine for dry eye?
Yes. Oral pilocarpine stimulates tear and salivary glands. In Korea it is approved for Sjögren’s-related dry eye or dry mouth (and radiation-related dry mouth). It requires a prescription after examination.
Is pilocarpine better than artificial tears?
Not necessarily. In the 2026 randomized trial, both helped, but artificial tears did better on tear-film stability and dry-eye–related quality of life.
Can it help after cataract or LASIK/LASEK?
Direct evidence for oral pilocarpine after those procedures is limited. Assess cause first and usually start with topical strategies.
Will the Schirmer test definitely improve?
Not consistently across studies. In the 2003 Sjögren’s trial, symptoms and staining improved without a clear between-group Schirmer difference.
What is the most common side effect?
Sweating. Urinary frequency, nausea, diarrhea, flushing, headache, and blurred vision can also occur. Asthma, certain eye diseases, or cardiovascular disease need medical review before use.
Can I use artificial tears with oral pilocarpine?
Trials have used combinations. Whether to combine them depends on your dry eye type and health. Do not stop other prescribed treatments on your own.
If my eyes and mouth are both dry, do I have Sjögren’s?
Not always — medications, other conditions, and environment can dry both. Persistent combined dryness is a reason to evaluate for Sjögren’s.
Bottom line
Good dry eye care starts with the cause — too little watery tear, too much evaporation, inflammation, or a mix — not with adding the newest option by default.
Oral pilocarpine has meaningful evidence for Sjögren’s-related eye and mouth dryness. That evidence should not be copied wholesale onto routine dry eye or every post-surgery case, and systemic side effects such as sweating must be weighed carefully.
“Good treatment is not the newest medicine — it is the one that fits the cause of your dry eye.”
If you work or live near Guro, Geumcheon, Yeongdeungpo, Gwanak, or Dongjak, or around Guro / Gasan Digital Complex, and dryness keeps interrupting screen work or night driving, an ocular surface evaluation can clarify the next step.
One-line summary: Oral pilocarpine can help selected patients — especially Sjögren’s-related dryness — but it is not suitable for every dry eye case and requires attention to systemic side effects.
nuneHIM Eye Center (눈에힘안과의원)
Dr. Daniel Jinhag Baik, MD — Head Director, Ophthalmologist
5F Kwanghee Bldg, 551 Siheung-daero, Guro-gu, Seoul (near Guro Digital Complex & Gasan Digital Complex stations)
Website: www.nunehim.com · YouTube: 안과 백선생
Naver Booking: https://booking.naver.com/booking/13/bizes/923695
References
1. Vivino FB, et al. Pilocarpine Tablets for the Treatment of Dry Mouth and Dry Eye Symptoms in Patients With Sjögren Syndrome. Arch Intern Med. 1999;159:174–181. PubMed: https://pubmed.ncbi.nlm.nih.gov/9927101/ DOI: https://doi.org/10.1001/archinte.159.2.174
2. Tsifetaki N, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren’s syndrome. Ann Rheum Dis. 2003;62:1204–1207. PubMed: https://pubmed.ncbi.nlm.nih.gov/14644860/ DOI: https://doi.org/10.1136/ard.2002.003889
3. Aragona P, et al. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjögren’s syndrome. Br J Ophthalmol. 2006;90:166–170. PubMed: https://pubmed.ncbi.nlm.nih.gov/16424527/ DOI: https://doi.org/10.1136/bjo.2005.078865
4. Saad EME, et al. Efficacy and safety of pilocarpine as a secretagogue versus artificial tears in the management of dry eye disease. Med Hypothesis Discov Innov Ophthalmol. 2026;15:1–9. DOI: https://doi.org/10.51329/mehdiophthal1536
5. Miura M, et al. Prevalence and Characteristics of Dry Eye Disease After Cataract Surgery: A Systematic Review and Meta-Analysis. Ophthalmol Ther. 2022;11:1309–1332. PubMed: https://pubmed.ncbi.nlm.nih.gov/35534685/ DOI: https://doi.org/10.1007/s40123-022-00513-y
6. Ta H, et al. Dry eye post-cataract surgery: a systematic review and meta-analysis. BMC Ophthalmol. 2025;25:18. PubMed: https://pubmed.ncbi.nlm.nih.gov/39806338/ DOI: https://doi.org/10.1186/s12886-024-03841-8
7. Jones L, et al. TFOS DEWS III: Management and Therapy. Am J Ophthalmol. 2025;279:289–386. PubMed: https://pubmed.ncbi.nlm.nih.gov/40467022/ DOI: https://doi.org/10.1016/j.ajo.2025.05.039
8. Korean prescribing information / labeling for oral pilocarpine hydrochloride 5 mg (indications and precautions).
This article is for general medical education based on published studies and Korean product labeling information as of October 2026. It does not recommend prescribing or purchasing any specific prescription medicine, and it is not a substitute for individual diagnosis or treatment. Decisions about dry eye care should be made after an examination by an ophthalmologist.
Leave a Reply